Short answer · Medically reviewed summary · Last updated: 2026-05-08
Fetal Valproate Syndrome is classified under the ICD-10-CM code Q86.8 (Other specified congenital malformation syndromes due to known exogenous causes) and was historically categorized under ICD-9-CM code 760.79 (Other specified nonteratogenic effects of other drugs). These codes are used by healthcare providers to document the specific developmental and physical impacts resulting from prenatal exposure to valproic acid or its derivatives. What is Fetal Valproate Syndrome? Fetal Valproate Syndrome occurs when a developing fetus is exposed to valproate medications, commonly prescribed for epilepsy, bipolar disorder, or migraines.
ICD10 code of Fetal Valproate Syndrome and ICD9 code
ICD-10 and ICD-9 codes for Fetal Valproate Syndrome, with classification details for clinicians, coders and patients.
Fetal Valproate Syndrome is classified under the ICD-10-CM code Q86.8 (Other specified congenital malformation syndromes due to known exogenous causes) and was historically categorized under ICD-9-CM code 760.79 (Other specified nonteratogenic effects of other drugs). These codes are used by healthcare providers to document the specific developmental and physical impacts resulting from prenatal exposure to valproic acid or its derivatives.
What is Fetal Valproate Syndrome?
Fetal Valproate Syndrome occurs when a developing fetus is exposed to valproate medications, commonly prescribed for epilepsy, bipolar disorder, or migraines. The syndrome is characterized by a specific pattern of physical, cognitive, and developmental features. Because Fetal Valproate Syndrome is an environmentally induced condition rather than a genetic one, it requires careful monitoring by a multidisciplinary medical team throughout childhood.
What are the clinical features of Fetal Valproate Syndrome?
The presentation of Fetal Valproate Syndrome varies significantly among affected individuals, but clinical literature frequently highlights a constellation of common findings:
- Distinctive facial features: Including epicanthal folds, a flat nasal bridge, and a thin upper lip.
- Skeletal anomalies: Such as radial ray defects or limb malformations.
- Neurodevelopmental challenges: Intellectual disability, autism spectrum disorder, or specific learning deficits.
- Neurological concerns: Increased risk of microcephaly or delayed motor development.
How is Fetal Valproate Syndrome diagnosed?
Diagnosis of Fetal Valproate Syndrome is primarily clinical, based on a documented history of maternal valproate exposure during pregnancy combined with the presence of characteristic physical and developmental signs. There is no single genetic test to confirm Fetal Valproate Syndrome; instead, diagnosis involves a thorough evaluation by a clinical geneticist or a dysmorphologist to rule out other genetic syndromes with overlapping features.
Next steps
- Consult with a clinical geneticist to review the specific exposure history and developmental profile.
- Connect with the Fetal Valproate Syndrome community at DiseaseMaps.org to share experiences with others who understand the unique challenges of this diagnosis.
- Request referrals for early intervention services, including speech, occupational, and physical therapy.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Fetal Valproate Syndrome.
- Orphanet: Valproic acid embryopathy (ORPHA:99912).
- OMIM: Valproate embryopathy (Entry #606277).
